The exhale podcast, brought to you by Vitalograph

Episode # 55 The Application of HRF Inhibitor to Asthma Therapy

Toshiaki Kawakami, M.D., Ph.D.

Professor, La Jolla Institute for Immunology Center for Autoimmunity and Inflammation

We spoke with Professor Toshiaki Kawakami or Toshi as his colleagues and students call him. He is one of the leaders of La Jolla Institute for Immunology was established in 1988 by a coalition of leaders from academia and industry. These leaders envisioned a unique and dynamic partnership between basic science and applied research, one that would lead to breakthroughs in the understanding of the immune system and improve human health through the development of treatments and cures for immune system disorders. Dr. Toshia’s lab studies inflammatory diseases such as allergic asthma, food allergies and Crohn’s disease, which have been rising in prevalence for the last several decades. He is particularly interested in histamine-releasing factor (HRF) and its role in promoting inflammation in the lung and gut.

La Jolla Institute for Immunology Center for Autoimmunity and Inflammation Website:

https://www.lji.org/research/research-centers/center-for-autoimmunity-and-inflammation/

 

Episode # 54 Pulmonary Fibrosis, An Advocate’s Story

Teresa Barnes, Chief Executive Warrior

She first became involved with the PF community after losing five family members to IPF. Teresa began her career in journalism and has used those skills as she has navigated the worldwide PF community, seeking out-of-the-box solutions for treating PF. Teresa was a founder of the first IPF patient organization, the Coalition for Pulmonary Fibrosis back in 2001. She has served on multiple boards, including ATS, where she spearheaded multiple advocacy efforts. A member of PF Warriors for five years, Teresa will help us to open doors around the world.

PF Warriors Website

https://pfwarriors.com/

Episode # 53 What is Acute Respiratory Distress Syndrome (ARDS)?

Paula Blonski, President ARDS Alliance

Rick Bressler, ARDS Survivor

Today we had an interesting conversation with Paula Blonski, President-ARDS Alliance and Rick Bressler a patient who had Covid double lung pneumonia, Covid induced ARDS, but he ultimately needed a double lung transplant to survive.  Acute respiratory distress syndrome (ARDS) is an acute, diffuse, inflammatory form of lung injury and life-threatening condition in seriously ill patients, characterized by poor oxygenation, pulmonary infiltration, and acute onset.

ARDS Alliance Website

https://ardsalliance.org/

Episode # 52 Trikafta and Me

Annaka Haynes is a nursing student who has had Cystic Fibrosis since she was 6 weeks old. Trikafta developed by Vertex Pharmaceuticals was first approved by the FDA on October 21, 2019. This treatment is a triple combination regimen for cystic fibrosis patients starting at ages 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.

Episode # 51 How Asthma Diagnoses can be improved with precision medicine

Rory Chan (MBChB, MRCP(UK), PhD) is a senior respiratory registrar currently working in Ninewells Hospital, Dundee, United Kingdom

Dr. Chan recently completed his PhD relating to precision medicine in severe asthma and has published more than 20 first-author peer reviewed papers in this area. He is a Honorary Clinical Lecturer at the University of Dundee, an Early Career Editor at CHEST, and the principal investigator of two phase IV biologic clinical trials in severe asthma.

Episode # 50 Leading One of the Nation’s Most Active, Experienced, and Innovative Lung Transplant Programs

Kevin Carney, ANP-BC- Director of Temple Lung Health Center

Kevin Carney is a certified Adult Nurse Practitioner (ANP-BC) and Director of The Temple Lung Center service line. He oversees Nurse Practitioners and Physician Assistants who work for the Pulmonary, Lung Transplant, and Respiratory Intensive Care services at Temple University Hospital. Temple is home of the most active Lung Transplant and Bronchoscopic Lung Volume Reduction (BLVR) programs in the United States. He oversees Nurse Practitioners and Physician Assistants who work for the Pulmonary, Lung Transplant, and Respiratory Intensive Care services.

 Involvement with professional organizations include the American Board for Transplant Certification (ABTC), where he serve on the Board of Governors, and the International Society of Heart and Lung Transplant (ISHLT) as a member of the Advanced Lung Failure and Transplantation Interdisciplinary Network Steering Committee.

Episode # 49 Advocating for COPD: Awareness, Resources and Research

We believe in the power of the patient voice to provide inspiration and hope to others in similar situations. That’s why we were thrilled to sit down with John Linnell, an individual who lives with COPD and who, since his diagnosis, has been advocating for COPD awareness, resources, and research.

 

John Linnell, COPD Patient

John was diagnosed in 2005 and his journey led him to key roles in advocacy, in which he is active. John is a member of the Board of Directors for the US COPD Coalition and is an Advocacy Captain for the COPD Foundation. He serves on the Executive Board of Directors for EFFORTS (an international support group for the COPD community), a member of the Governing Board for the COPD PPRN (Patient Powered Research Network), and the Board of Directors of Right2Breathe, a nonprofit emphasizing early diagnosis and patient education. John also sat as a Consumer Reviewer for CDMRP (Congressional Directed Medical Research Programs) for the Department of Defense and now mentors new Consumer Reviewers.

 

John was a Co-investigator for a 3-year PCORI-funded study at Johns Hopkins: “Impact of a Peer Support Program Amongst COPD Patients and Their Caregivers”.

 

CMS/Medicare recently appointed John to a term as a patient representative on a Technical Expert Panel for the 2024 Impact Assessment of CMS Quality and Efficiency Measures.
He also was asked to join the Patient Engagement Collaborative for the FDA. He also is a Patient Scholar for DIA (Drug Information Association) and spoke at their annual international conference this past year.

 

In addition, John is a frequent speaker and/or panel member at numerous national conferences dealing with both respiratory issues as well as advising digital health start-up enterprises as a Patient Advisor.

Episode # 48 Non-Invasive Ventilation/Nasal High Flow Therapies

We had a delightful conversation with Dr. Kirk Hinkley and Matt Pavlichko, RT for at Vapotherm. We discuss their high velocity therapy and how it saved lives during the pandemic and continues to be an alternative method for patients who are mask-intolerant.

Kirk Hinkley, MD, FACEP

Dr. Kirk Hinkley is Vapotherm’s Director of Education and a board-certified Emergency Medicine Physician having completed his EM residency at Wright State University/Wright Patterson AFB in 2007. He is the Medical Director of Commonwealth Health EMS and City of Scranton Fire Dept, where he maintains clinical oversight of several EMS units, and practices as an Emergency Physician in the Scranton, PA area.  He went to medical school on a United States Air Force Scholarship and served in Operations Iraqi Freedom and Enduring Freedom as a critical care air transport team leader and flight surgeon. Dr. Hinkley is an experienced user of high velocity therapy for the adult and pediatric patient.

Matthew S. Pavlichko, MS, RRT-NPS

Matt is the Director of Professional Development and Education, Respiratory Therapy at Vapotherm.

He has been in the respiratory therapy field for over 25 years, practicing in South Central Pennsylvania and North Carolina as a respiratory therapist, educator, manager, and director, managing all aspects of respiratory care. 

We want to bring you the most relevant podcast, to do that we need your feedback. Please take our 5-to 7 minute survey, so that we can provide you an even better Podcast experience.

Survey Link-https://lp.constantcontactpages.com/sv/qeVnHmK/PodcastSurvey 

 

 

Episode # 47 Can Stem Cell Therapies Reverse Lung Disease Damage?

Featured Guest: Dr. James Veltmeyer and Dr. Thomas Ichim

Dr. Veltmyer- Recognized as one of San Diego's leading physicians and surgeons, Dr. Veltmeyer brings a unique combination of management and medicine experience to every position he holds. Known for his dedication to quality care and his efforts to restore the doctor-patient relationship, he consistently ranks in the top 1% to 2% for patient satisfaction.

 

Dr. Ichim has a track record of success in the area of clinical translation of cellular and immune-based therapies having successfully obtained four Investigational New Drug Application clearances with the FDA for products he developed.

 

We want to bring you the most relevant podcast, to do that we need your feedback. Please take our 5-to 7 minute survey, so that we can provide you an even better Podcast experience.

Survey Link-https://lp.constantcontactpages.com/sv/qeVnHmK/PodcastSurvey 

 

 

 

Episode # 46 What is Global Lung Function Initiative or GLI Network

Brendan Cooper-Consultant Clinical Scientist & Hon. Professor of Respiratory & Sleep Physiology

Brendan is a clinical scientist and professor in respiratory and sleep physiology, and leads one of the largest lung function departments in Europe. He was elected as Head of ERS Assembly 9, Chairman of Association for Respiratory Technology & Physiology, then its first President and now he is first President of the Academy for Healthcare Science. He enjoys leading professional standards of quality and promoting science with innovation in respiratory physiology. Brendan has published 160+ peer-reviewed papers on his scientific work which underpins his research experience.

We want to bring you the most relevant podcast, to do that we need your feedback. Please take our 5-to 7 minute survey, so that we can provide you an even better Podcast experience.

Survey Link-https://lp.constantcontactpages.com/sv/qeVnHmK/PodcastSurvey